Cristian G. Bologa

Cristian G. Bologa

Auto-generated profile, based on publicly available information

Cristian G. Bologa

Department of Internal Medicine, School of Medicine, University of New Mexico Health Sciences Center, 1 University of New Mexico, MSC10 5550, Albuquerque, NM, 87131, United States, 1 505-272-9709

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2006 in Nature Chemical Biology
Verified
Journal Article
Closed access
CBCristian G Bologa
Cristian G Bologa
CRChetana M Revankar
Chetana M Revankar
SYSusan M Young
Susan M Young
BEBruce S Edwards
Bruce S Edwards
JAJeffrey B Arterburn
Jeffrey B Arterburn
Eric R. ProssnitzEric R. Prossnitz
Eric R. Prossnitz

3 May 2009 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
MDMegan K Dennis
Megan K Dennis
RBRitwik Burai
Ritwik Burai
CRChinnasamy Ramesh
Chinnasamy Ramesh
WPWhitney K Petrie
Whitney K Petrie
SASara N Alcon
Sara N Alcon
Eric R. ProssnitzEric R. Prossnitz
Eric R. Prossnitz
Estrogen is central to many physiological processes throughout the human body. We have previously shown that the G protein–coupled receptor GPR30 (also known as GPER), in addition to classical nuclear estrogen receptors (ERα and ERβ), activates cellular signaling pathways in response to estrogen. In order to distinguish between the actions of classical estrogen receptors and GPR30, we have previously characterized G-1 (1), a selective agonist of GPR30. To complement the pharmacological properties of G-1, we sought to identify an antagonist of GPR30 that displays similar selectivity against the classical estrogen receptors. Here we describe the identification and characterization of G15 (2), a G-1 analog that binds to GPR30 with high affinity and acts as an antagonist of estrogen signaling through GPR30. In vivo administration of G15 revealed that GPR30 contributes to both uterine and neurological responses initiated by estrogen. The identification of this antagonist will accelerate the evaluation of the roles of GPR30 in human physiology.

1 January 2011 in Drug Discovery Today: Therapeutic Strategies
Verified
Journal Article
Closed access
TOTudor I. Oprea
Tudor I. Oprea
JBJulie E. Bauman
Julie E. Bauman
CBCristian G. Bologa
Cristian G. Bologa
TBTione Buranda
Tione Buranda
ACAlexandre Chigaev
Alexandre Chigaev
LSLarry A. Sklar
Larry A. Sklar

1 November 2011 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
MDMegan K. Dennis
Megan K. Dennis
AFAngela S. Field
Angela S. Field
RBRitwik Burai
Ritwik Burai
CRChinnasamy Ramesh
Chinnasamy Ramesh
WPWhitney K. Petrie
Whitney K. Petrie
Eric R. ProssnitzEric R. Prossnitz
Eric R. Prossnitz

1 June 2010 in Current Biology
Verified
Journal Article
Closed access
JSJay P. Slack
Jay P. Slack
ABAnne Brockhoff
Anne Brockhoff
CBClaudia Batram
Claudia Batram
SMSusann Menzel
Susann Menzel
CSCaroline Sonnabend
Caroline Sonnabend
WMWolfgang Meyerhof
Wolfgang Meyerhof

29 November 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
KKKeith J Kelleher
Keith J Kelleher
TSTimothy K Sheils
Timothy K Sheils
SMStephen L Mathias
Stephen L Mathias
JYJeremy J Yang
Jeremy J Yang
VMVincent T Metzger
Vincent T Metzger
TOTudor I Oprea
Tudor I Oprea
The Illuminating the Druggable Genome (IDG) project aims to improve our understanding of understudied proteins and our ability to study them in the context of disease biology by perturbing them with small molecules, biologics, or other therapeutic modalities. Two main products from the IDG effort are the Target Central Resource Database (TCRD) (http://juniper.health.unm.edu/tcrd/), which curates and aggregates information, and Pharos (https://pharos.nih.gov/), a web interface for fusers to extract and visualize data from TCRD. Since the 2021 release, TCRD/Pharos has focused on developing visualization and analysis tools that help reveal higher-level patterns in the underlying data. The current iterations of TCRD and Pharos enable users to perform enrichment calculations based on subsets of targets, diseases, or ligands and to create interactive heat maps and UpSet charts of many types of annotations. Using several examples, we show how to address disease biology and drug discovery questions through enrichment calculations and UpSet charts.